Symptoms, risk, screening and diagnostic confirmation

Detect Pheochromocytoma and Paraganglioma is about choosing the right test for the right risk.

A pheochromocytoma/paraganglioma detection guide covering episodic hypertension, palpitations, sweating, headaches, plasma/urine metanephrines, CT/MRI, functional imaging and genetics.

Screening reality Symptoms not to ignore

Educational, not personal medical advice. Episodes of severe hypertension, pounding headache, sweating, palpitations, panic-like spells, adrenal incidentaloma or family syndrome should prompt biochemical testing.

Metanephrines

are the first-line biochemical test.

Adrenal

pheochromocytoma starts in adrenal medulla.

Paraganglioma

can occur outside adrenal glands.

Genes

SDHx, VHL, RET, NF1 and others matter.

Brief outline

What pheochromocytoma and paraganglioma means.

Pheochromocytomas and paragangliomas are catecholamine-producing neuroendocrine tumors. Some are hereditary, and some are malignant by behavior rather than microscope appearance.

Abdominal MRI example — CT/MRI localizes adrenal or extra-adrenal tumors.

Detection frame

Screening is for people without symptoms. Diagnosis is for symptoms, abnormal examination, family history, imaging findings or abnormal labs. The same test can be sensible in one setting and misleading in another.

Do not ignore

Symptoms and signs not to ignore.

Paroxysmal hypertensionSpells can be dramatic or subtle.

Headache/sweating/palpitationsClassic triad, not always complete.

Panic-like attacksCan be mislabelled anxiety.

Adrenal incidentalomaNeeds hormone assessment.

Family historySyndromic clues matter.

Mass effectNon-secreting paragangliomas can present by location.

Risk and genetics

Demographics, risks and genetics.

SDHx genesImportant hereditary paraganglioma risk.

MEN2/RETCan include pheochromocytoma.

VHL/NF1Classic syndromic associations.

Young/bilateral/multifocalRaises genetic suspicion.

Prior tumorsRecurrence/metastasis can occur.

Most sporadicBut genetics yield is high enough to consider.

Screening

Who should actually be screened?

No average-risk screening exists. Known hereditary syndromes require biochemical and imaging surveillance.

First line

Plasma free or urine fractionated metanephrines

Most useful biochemical screening tests.

Caution

False positives

Stress, drugs and sampling conditions can mislead.

Localize

CT/MRI adrenal/neck/chest/abdomen

Finds adrenal or extra-adrenal tumors.

Functional

MIBG, FDG PET, DOTATATE PET

Chosen by genotype and disease pattern.

Genetics

Germline testing

Often recommended because inherited disease is common.

Safety

Alpha blockade before surgery

Detection changes perioperative safety.

Images, labs and tissue

Useful tests and what they can miss.

Detection usually needs a chain: suspicion, imaging or lab triage, tissue or cytology when needed, then pathology and molecular testing where it changes management.

PET-CT example — Functional imaging can map metastatic or multifocal disease.

Blood test example — Biochemistry comes before localization in most cases.

Pros, cons and controversy

Benefits, harms and the false-positive problem.

The harm is missing a dangerous but treatable cause of hypertensive crises. The counter-risk is chasing mildly abnormal metanephrines without proper sampling context.

Pheochromocytoma and Paraganglioma detection trials DetectCancer.org hub

Sources and trials

Good starting points.

NCI pheochromocytoma/paragangliomaOverview, genetics and diagnosis. ClinicalTrials.gov PPGL detectionBiomarker and imaging trials.